Search our Database of Scientific Publications and Authors

I’m looking for a

    4376 results match your criteria Urticaria Chronic

    1 OF 88

    A Case of Schnitzler's Syndrome without Monoclonal Gammopathy-Associated Chronic Urticaria Treated with Anakinra.
    Yonsei Med J 2018 Jan;59(1):154-157
    Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
    Chronic urticaria may often be associated with interleukin (IL)-1-mediated autoinflammatory disease, which should be suspected if systemic inflammation signs are present. Here, we report a case of Schnitzler's syndrome without monoclonal gammopathy treated successfully with the IL-1 receptor antagonist anakinra. A 69-year-old man suffered from a pruritic urticarial rash for 12 years. Read More

    Chronic urticaria in most patients is poorly controlled. Results of the development, validation, and real life application of the arabic urticaria control test.
    Saudi Med J 2017 Dec;38(12):1230-1236
    Hotel-Dieu de France, Faculty of Pharmacy, St Joseph University, Beirut, Lebanon. E-mail.
    Objectives: To translate and linguistically validate the urticaria control test (UCT) to/for Arabic speakers. No Arabic version of the UCT is available to assess disease control in patients with chronic urticaria (CU). Secondary objectives were to assess disease control in Lebanese CU patients and determine influence factors. Read More

    IL-24 is a common and specific autoantigen of IgE in chronic spontaneous urticaria.
    J Allergy Clin Immunol 2017 Dec 2. Epub 2017 Dec 2.
    Dept. of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany.
    Background: The efficacy of omalizumab (anti-IgE) and elevated IgE levels in chronic spontaneous urticaria (CSU) suggest autoallergic mechanisms.

    Objective: To identify autoallergic targets of IgE in CSU patients.

    Methods: Sera of CSU patients together with idiopathic anaphylaxis patients and healthy controls (seven of each) were screened for IgE-autoantibodies using an array of >9,000 proteins. Read More

    Pneumocystis jirovecii pneumonia induced by low-dose methotrexate in a patient with chronic urticaria.
    An Bras Dermatol 2017 May-Jun;92(3):401-403
    Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center - Taipei, Taiwan, Republic of China.
    Methotrexate has immunosuppressive effects and is administered for refractory chronic urticaria. We present a case of Pneumocystis jirovecii pneumonia in a patient with refractory chronic urticaria managed by low-dose weekly methotrexate treatment (total cumulative dose 195mg). Our study highlights the importance of providing prompt diagnosis and treatment of Pneumocystis jirovecii pneumonia in patients with chronic urticaria under methotrexate therapy. Read More

    Clinical Course of Chronic Spontaneous Urticaria in the Korean Adult Population.
    Allergy Asthma Immunol Res 2018 Jan;10(1):83-87
    Department of Dermatology, The Catholic University of Korea College of Medicine, Seoul, Korea.
    Knowledge of the clinical course of chronic spontaneous urticaria (CSU) remains unclear. The purpose of our study was to investigate the clinical course of CSU in the Korean adult population. Each patient in the CSU group who was defined by disease codes between 2003 and 2007 was tracked whether he or she went into remission or not until 2013. Read More

    The effect of anti-IgE therapy in knee osteoarthritis: a pilot observational study.
    J Biol Regul Homeost Agents 2017 Oct-Dec,;31(4 Suppl. 1):1-5
    Clinical Orthopaedics, Università Politecnica delle Marche, Ancona, Italy
    Osteoarthritis is a whole-joint disease and its pathogenesis remains poorly understood. Recent evidence proposed the importance of the innate immune system as trigger of synovium inflammation following the degeneration of cartilage. Moreover, synovial mast cells (MCs) might be correlated with pain and disability reported by patients. Read More

    Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature.
    Photodermatol Photoimmunol Photomed 2017 Nov 24. Epub 2017 Nov 24.
    Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
    Background: Solar urticaria (SU) is a rare photodermatosis. Treatment is challenging and outcomes are often disappointing. Omalizumab is an anti-IgE, currently approved for treatment of chronic spontaneous urticaria. Read More

    Detection of circulating IgG autoantibody to FcεRIα in sera from chronic spontaneous urticaria patients.
    J Microbiol Immunol Infect 2017 Nov 14. Epub 2017 Nov 14.
    Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea. Electronic address:
    Backgrounds: Chronic spontaneous urticaria (CSU) is a common skin disorder characterized by itchy wheals of at least 6 weeks in duration, wherein the autoimmune mechanism is involved to activate IgE receptors (FcεRIα) on mast cells. We aimed to assess levels of IgG autoantibody against FcεRIα in sera from CSU patients using dot-blot immunoassay.

    Methods: We performed a hospital-based cross-sectional study of 125 CSU patients (64 ASST-positive, 61 ASST-negative) and 64 age-and sex-matched healthy controls. Read More

    Evaluation of 1,25-dihydroxyvitamin D3 Pathway in Patients with Chronic Urticaria.
    QJM 2017 Nov 20. Epub 2017 Nov 20.
    Department of Clinical Biochemistry, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
    Background: Previous studies showed the role of vitamin D (Vit D) on the progression of chronic urticaria. To the best of our knowledge, there are no other results regarding the contribution of single nucleotide polymorphisms (SNPs) in the vitamin D receptor (VDR) and vitamin D binding protein (VDBP) genes in Chronic Urticaria (CU).

    Aim: In the present study, we investigated the Vit pathway and the association between VDR and VDBP gene polymorphisms and CU risk in Iranian population. Read More

    Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
    Clin Exp Allergy 2017 Nov 22. Epub 2017 Nov 22.
    Department of Rheumatology, Immunology and Allergology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
    Background: Omalizumab has been shown to be effective in treating chronic spontaneous urticaria (CSU). The reduction of FcεRI receptor density on the surface of basophils and mast cells is thought to play a major role in its effectiveness. We conducted a double-blind, randomized, placebo-controlled trial to investigate the mode of action of omalizumab in patients with antihistamine-resistant CSU. Read More

    Prevalence of papular urticaria caused by flea bites and associated factors in children 1-6 years of age in Bogotá, D.C.
    World Allergy Organ J 2017 7;10(1):36. Epub 2017 Nov 7.
    Allergy Section, Hospital Universitario Fundación Santa Fe de Bogotá, Faculty of Medicine, Universidad de los Andes, Bogotá, Colombia.
    Background: Papular urticaria is a chronic inflammatory disease caused by exposure to arthropod bites. The disease has been reported in children attending medical centers, but the causes as the risk factors associated with the disease have not been established. The objective of this study was to determine the prevalence of papular urticaria caused by flea bite and identify the risk factors in children between 1 to 6 years of age in Bogotá D. Read More

    The XTEND-CIU study: long term use of Omalizumab in Chronic Idiopathic Urticaria.
    J Allergy Clin Immunol 2017 Nov 10. Epub 2017 Nov 10.
    University of South Florida, Tampa, Fla.
    These data support omalizumab safety and efficacy in patients with antihistamine-resistant CIU/CSU to 48 weeks and provide evidence of omalizumab re-treatment efficacy and safety. Read More

    The Prevalence of Periodontitis Is Increased in Psoriasis and Linked to Its Inverse Subtype.
    Skin Pharmacol Physiol 2017 Nov 2;30(6):324-328. Epub 2017 Nov 2.
    Department of Dermatology, Medical University of Graz, Graz, Austria.
    Periodontitis and psoriasis are suggested to be co-occurring, chronic inflammatory conditions with overlapping characteristics. However, respective evidence is rare and data on risk factors of periodontitis in psoriasis patients are minimal. The aim of this study was to expand the evidence of psoriasis-associated periodontitis and establish a potential risk profile for periodontitis. Read More

    C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria.
    Allergy 2017 Nov 12. Epub 2017 Nov 12.
    Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
    Background: Elevated levels of C-reactive protein (CRP), a sensitive marker of inflammation, have been consistently reported in chronic spontaneous urticaria (CSU). Here, we retrospectively analyzed data from 1253 CSU patients from 2 centers to answer the following questions: (i) What is the prevalence of elevated levels of CRP in CSU? (ii) Why do CSU patients show elevated levels of CRP? (iii) Are elevated CRP levels relevant?

    Methods: Serum levels of CRP were measured by the nephelometric method. We collected information regarding various laboratory tests including ESR, CBC with differential, D-dimer, fibrinogen, C3, C4, IL-6, etc. Read More

    Treatment of chronic spontaneous urticaria: Immunomodulatory approaches.
    Clin Immunol 2017 Nov 9. Epub 2017 Nov 9.
    Department of Dermatology, Saint-Luc University Hospital, Université catholique de Louvain, Brussels, Belgium; Institute of Experimental and Clinical Research, Pole of Pneumology, ENT and Dermatology, Université catholique de Louvain, Brussels, Belgium.
    This paper summarizes and reviews the mechanisms of action and data concerning efficacy of recommended treatments as well as other treatments that have been tested, independently of the outcomes, in the management of chronic spontaneous urticaria. Due to the central role of mast cells and histamine in the pathophysiology of this disease, H1-antihistamines remain the first-line treatment. However, current knowledge about this complex disease, also recognizes an important role for T lymphocytes, B lymphocytes, and autoantibodies. Read More

    The Urticaria Activity Score-Validity, Reliability, and Responsiveness.
    J Allergy Clin Immunol Pract 2017 Nov 8. Epub 2017 Nov 8.
    Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany. Electronic address:
    Background: Chronic spontaneous urticaria is characterized by fluctuating symptoms. Its activity is assessed with the urticaria activity score (UAS). Two versions of the urticaria activity score used for 7 consecutive days (UAS7) are available: (1) The guideline-recommended UAS7, with once-daily documentation, and (2) the UAS7TD, with twice-daily documentation. Read More

    [Cryopyrin-associated periodic syndromes].
    Rev Med Interne 2017 Oct 27. Epub 2017 Oct 27.
    Filière maladies rares FAI2R, 75000 Paris, France; Assistance publique-Hôpitaux de Paris, 75000 Paris, France; Service de médecine interne, centre de référence national maladies rares pour les maladies auto-inflammatoires et l'amylose (CEREMAIA), hôpital Tenon, université Pierre-et-Marie-Curie, 4, rue de la Chine, 75020 Paris, France.
    Cryopyrin-associated periodic syndromes (CAPS) are linked to one single gene mutations, however they are associated with 3 syndromes, which are, from the mildest to the most severe phenotype familial cold urticaria, Muckle-Wells syndrome and chronic, infantile, neurologic, cutaneous, articular (CINCA) syndrome also called neonatal-onset multisystem inflammatory disease (NOMID). Autosomic dominant inheritance is present in most cases but in CINCA/NOMID syndrome where neomutations are more common. Mutations in the gene encoding cryopyrin, NLRP3, are associated with deregulation of caspase-1 activity, excessive interleukin-1 production and an autoinflammatory syndrome, which in familial cold urticaria and Muckle-Wells syndrome may be triggered or worsened by exposure to coldness. Read More

    Prevalence and incidence of chronic spontaneous urticaria in the entire Korean adult population.
    Br J Dermatol 2017 Nov 6. Epub 2017 Nov 6.
    Department of Medical Statistics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
    Ethnic differences and temporal trends in the epidemiology of chronic spontaneous urticaria (CSU) are not well understood, especially in East Asia.1-3 The aim of our study was to investigate trends in the prevalence and incidence of CSU among adult Korean subjects from 2006 to 2014 using a nationwide, population-based study. This article is protected by copyright. Read More

    Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study.
    Allergol Int 2017 Nov 1. Epub 2017 Nov 1.
    Novartis Pharma AG, Basel, Switzerland. Electronic address:
    Background: Omalizumab, a humanized anti-IgE monoclonal antibody, proved efficacious and well tolerated in patients with chronic spontaneous urticaria (CSU) refractory to H1 antihistamines (H1AH) in the POLARIS study (NCT02329223), a randomized, double-blind, placebo-controlled trial in East Asian patients. However, data in Japanese patients, who have specific baseline characteristics (e.g. Read More

    Analysis of pediatric dermatology inpatient consultations in a pediatric teaching hospital.
    Arch Argent Pediatr 2017 12;115(6):e377-e384
    Ataturk Research and Training Hospital, Department of Dermatology, Izmir, Turkey.
    Introduction: Although skin diseases are associated with low rate of hospitalization, dermatological manifestations are frequent in hospitalized patients. The aim of the study was to describe the inpatient dermatological consultations in a pediatric teaching hospital.

    Population And Methods: Recorded data from inpatient pediatric dermatology consultation requests on a total of 539 consecutive inpatients (aged 0-18 years) from January 2004 to April 2010 were analyzed for consult diagnosis, dermatological disease group, primary diagnosis, requesting department, diagnostic pattern, treatment modality and referral to another department. Read More

    Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria.
    Eur J Dermatol 2017 Oct;27(5):455-463
    Department of Dermatology, Bispebjerg Hospital & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
    Omalizumab (a recombinant, humanized anti-immunoglobulin-E antibody) has been shown in three pivotal Phase III trials (ASTERIA I, II and GLACIAL) and real-world studies to be effective and well-tolerated for the treatment of chronic spontaneous urticaria (CSU), and is the only licensed third-line treatment for CSU. However, the definition of response to omalizumab treatment often differs between clinical trials, real-world studies, and daily practice of individual physicians globally. As such, a consensus definition of "complete", "partial" and "non-response" to omalizumab is required in order to harmonize treatment management and compare data. Read More

    The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
    Allergy 2017 Oct 30. Epub 2017 Oct 30.
    Department of Dermatology and Allergy, Dermatological Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
    Background: Omalizumab is an effective and well-tolerated treatment for chronic spontaneous urticaria (CSU). Markers and predictors of response are largely unknown, but needed to optimize omalizumab treatment. Omalizumab targets IgE, and IgE levels may be linked to the effects of treatment. Read More

    Real-world treatment patterns and outcomes of omalizumab use in patients with chronic idiopathic urticaria.
    Curr Med Res Opin 2017 Nov 10:1-5. Epub 2017 Nov 10.
    d University of Rochester Medical Center , Rochester , NY , USA.
    Objective: To examine treatment patterns, treatment response, and demographic and clinical characteristics of patients with chronic idiopathic urticaria (CIU) newly initiated on omalizumab therapy in real-world practice in the US.

    Methods: This retrospective observational cohort study used US claims data from the HealthCore Integrated Research Database (HIRD®) augmented with medical record data to identify CIU patients newly-treated with omalizumab (≥4 omalizumab claims within 6 months of initial claim; index date = first omalizumab claim date) between March 21, 2014 and October 31, 2015 and with ≥6 months pre- and ≥12 months post-index health plan eligibility. Study outcomes were captured from medical records for up to 12 months pre-index and up to 24 months post-index. Read More

    In chronic spontaneous urticaria, high numbers of dermal endothelial cells, but not mast cells, are linked to recurrent angio-oedema.
    Clin Exp Dermatol 2017 Oct 24. Epub 2017 Oct 24.
    Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany.
    Background: Chronic spontaneous urticaria (CSU) is an inflammatory skin disorder characterized by recurrent weals, angio-oedema or both. Recent studies have shown that the number of endothelial cells is increased in the skin of patients with CSU, but the underlying mechanisms and clinical implications of this are unclear.

    Aim: To evaluate whether mast cell (MC) or endothelial cell (EC) numbers correlate with CSU and whether they are relevant for disease duration, disease activity or the presence of clinical features. Read More

    Strongyloides stercoralis is associated with significant morbidity in rural Cambodia, including stunting in children.
    PLoS Negl Trop Dis 2017 Oct 23;11(10):e0005685. Epub 2017 Oct 23.
    Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland.
    Background: Strongyloides stercoralis is a soil-transmitted nematode that can replicate within its host, leading to long-lasting and potentially fatal infections. It is ubiquitous and highly prevalent in Cambodia. The extent of morbidity associated with S. Read More

    Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data.
    Allergy 2017 Oct 23. Epub 2017 Oct 23.
    Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
    Background: The X-ACT study aimed to examine the effect of omalizumab treatment on quality of life (QoL) in chronic spontaneous urticaria (CSU) patients with angioedema refractory to high doses of H1 -antihistamines.

    Methods: In X-ACT, a phase III, double-blind, placebo-controlled study, CSU patients (18-75 years) with ≥4 angioedema episodes during the 6 months before inclusion were randomized (1:1) to receive omalizumab 300 mg or placebo every 4 weeks for 28 weeks. Angioedema-related QoL, skin-related QoL impairment, and psychological well-being were assessed. Read More

    Itching for nail fashion: chronic urticaria and chronic hand dermatitis secondary to acrylate and methacrylate allergy in gel nail varnish.
    Clin Exp Dermatol 2017 Oct 23. Epub 2017 Oct 23.
    Department of Dermatology, Royal North Shore Hospital, St Leonards, NSW, Australia.
    Allergic contact dermatitis (ACD) secondary to acrylates and methacrylates is a well- described occurrence, particularly in those who wear or handle gel nail varnish. Management involves avoidance of the identified allergen. The cause of chronic urticaria (CI) is often not identified, and CU is not known to be associated with acrylates or methacrylates. Read More

    Interleukin 31 and skin diseases: A systematic review.
    Allergy Asthma Proc 2017 Nov;38(6):401-408
    Background: Although the pathophysiology of pruritus has been extensively studied in recent years, with many resultant advancements, management of pruritus is still enigmatic, particularly in chronic cutaneous diseases, such as atopic dermatitis, chronic urticaria, allergic contact dermatitis, cutaneous T-cell lymphoma, and uremic pruritus. The recent finding of the involvement of interleukin (IL) 31 in the pathogenesis of chronic pruritus has provided a novel approach to the management of chronic inflammatory skin disorders. The present report provided an in-depth overview of the role of IL-31 in chronic skin diseases and the possible diagnostic and therapeutic applications in the management of these diseases. Read More

    [Is it possible for chronic urticaria diagnostic approach to be simplified? A clinical data checklist].
    Rev Alerg Mex 2017 Jul-Sep;64(3):309-326
    Universidad Espíritu Santo, Samborondón, Ecuador.
    Background: Existing clinical guidelines do not offer an efficient alternative for the collection of data on relevant clinical traits during history and physical of the patient with chronic urticaria.

    Objective: Our aim was to provide a clinical data checklist together with its guide to allow for thorough information to be obtained and for a physical exam that identifies the main features and triggering factors of the disease to be carried out.

    Methods: A search was conducted for relevant literature on chronic urticaria in Medline, the Cochrane library and PubMed. Read More

    Does omalizumab modify a course of recalcitrant chronic spontaneous urticaria?: A retrospective study in Asian patients.
    J Dermatol 2017 Oct 17. Epub 2017 Oct 17.
    Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
    Omalizumab has been approved for the treatment of recalcitrant chronic spontaneous urticaria (CSU). However, it remains unanswered whether omalizumab modifies a CSU course. We aimed to study a course of CSU after omalizumab treatment in an Asian population. Read More

    Checklist for a complete chronic urticaria medical history: an easy tool.
    World Allergy Organ J 2017 3;10(1):34. Epub 2017 Oct 3.
    Respiralab, Respiralab Research Group, Guayaquil, Ecuador.
    Background: Existing guidelines do not offer a quick, efficient alternative to the patient's recollection of relevant clinical features during anamnesis and physical examination for chronic urticaria (CU). This study aimed to identify specific items reflecting the main characteristics of CU that should be included in a comprehensive medical history for patients with CU. We also aimed to clarify possible eliciting factors for CU to support accurate diagnosis of the disease. Read More

    Mediators of Inflammation and Angiogenesis in Chronic Spontaneous Urticaria: Are They Potential Biomarkers of the Disease?
    Mediators Inflamm 2017 5;2017:4123694. Epub 2017 Sep 5.
    Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
    In chronic spontaneous urticaria (CSU), different pathophysiological mechanisms, potentially responsible for the development of the disease, have been recently described. It is likely that the activation of skin mast cells with consequent release of histamine and other proinflammatory mediators is responsible for vasodilation in the lesional skin of CSU. However, the underlying causes of mast cell activation in the disease are largely unknown and remain to be identified. Read More

    Autoimmune comorbidity in chronic spontaneous urticaria: A systematic review.
    Autoimmun Rev 2017 Dec 14;16(12):1196-1208. Epub 2017 Oct 14.
    Charité - Universitätsmedizin Berlin, Department of Dermatology and Allergology, Charitéplatz 1, Berlin D-10117, Germany. Electronic address:
    Background And Objective: Numerous autoimmune diseases (AIDs) have been linked to chronic spontaneous urticaria (CSU). Here, we provide the first extensive and comprehensive evaluation of the prevalence of AIDs in patients with CSU and vice versa.

    Methods: A Pubmed and Google Scholar search was performed to identify studies reporting the prevalence of various AIDs in CSU and vice versa published before April 2017. Read More

    Chronic spontaneous urticaria and the extrinsic coagulation system.
    Allergol Int 2017 Oct 6. Epub 2017 Oct 6.
    Department of Dermatology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan. Electronic address:
    Chronic spontaneous urticaria (CSU) is a common skin disorder characterized by daily or almost daily recurring skin edema and flare with itch. Recently, the activation of the blood coagulation cascade has been suggested to be involved in CSU, but the trigger of the coagulation cascade remains unclear. In this article, we review recent understanding of the relationship between the pathogenesis of CSU and extrinsic coagulation reactions. Read More


    Epidemiology and comorbidities of patients with chronic urticaria in Korea: A nationwide population-based study.
    J Dermatol 2017 Oct 6. Epub 2017 Oct 6.
    Department of Dermatology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
    Few population-based studies have focused on the epidemiology and comorbidities of chronic urticaria (CU) or chronic spontaneous urticaria (CSU). The objective of this study was to obtain information on the epidemiology and comorbidities associated with CU and CSU in Korea. We conducted a cross-sectional analysis using a national health insurance database. Read More

    Anti-IgE Treatment for Disorders Other Than Asthma.
    Front Med (Lausanne) 2017 21;4:152. Epub 2017 Sep 21.
    Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Washington University in St. Louis School of Medicine, St. Louis, MO, United States.
    Immunoglobulin E (IgE) plays a key role in the pathogenesis of many allergic diseases. Thus, IgE-mediated immunologic pathways are an attractive target for intervention in allergic diseases. Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and has been used treat allergic asthma for over a decade. Read More

    Subcutaneous Autologous Serum Therapy in Chronic Spontaneous Urticaria.
    Indian J Dermatol 2017 Sep-Oct;62(5):505-507
    Department of Dermatology, D. Y. Patil Hospital, Navi Mumbai, Maharashtra, India.
    Background: There is a felt need for trying newer therapeutic modalities in patients with chronic spontaneous urticaria, especially in the subset of patients classified as non-responders to antihistamines. Autologous serum therapy is an upcoming modality of treatment, and we decided to study its efficacy by subcutaneous route.

    Aims: To evaluate the effectiveness of subcutaneous autologous serum therapy (AST) in CSU. Read More

    Evaluating Comorbidities, Natural History, and Predictors of Early Resolution in a Cohort of Children With Chronic Urticaria.
    JAMA Dermatol 2017 Sep 27. Epub 2017 Sep 27.
    Division of Allergy and Clinical Immunology, Department of Pediatrics, McGill University Health Centre, Montreal, Quebec, Canada.
    Importance: Chronic urticaria (CU) affects 0.1% to 0.3% of children. Read More

    1 OF 88